Tulobuterol tapes 2 mg for asthma and bronchitis

General information on Japanese Tulobuterol tapes 2 mg for asthma and bronchitis

Package details: 70 sheets

Manufacturer: Hisamitsu Pharmaceutical Company, Japan

Active ingredient: tulobuterol (chemical formula C12H18ClNO)

Medical effect: Tulobuterol tapes are effective for the treatment of the following diseases and conditions:

• bronchial asthma,
• acute bronchitis,
• chronic bronchitis,
• emphysema.

Contraindications and precautions: do not use for pregnant and breastfeeding women. Do not use for patients with hyperthyroidism, hypertension, heart disease, diabetes mellitus or atopic dermatitis.

If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Tulobuterol tapes 2 mg from Japan for asthma and bronchitis

For adults and children aged 9 years or over: apply a 2 mg tape at a time, once a day, to the chest, back or upper arm.

For children aged 3 to 8 years: apply a 1 mg tape at a time, once a day, to the chest, back or upper arm.

This medicine contains 2 mg of the active ingredient in a piece of tape. Clean the place of application before applying. Change the place of application every time. Do not apply the medicine to wounded or irritated areas.

Please note that children may remove the tape by themselves. Apply to a site where child cannot touch the tape.

How effective are Tulobuterol tapes 2 mg from Japan for asthma and bronchitis?

Tulobuterol is a long-acting beta2-adrenergic receptor agonist. It works by acting on β2 receptors of the bronchial smooth muscles. As a result, Tulobuterol tapes effectively treat respiratory distress due to airway obstructive disorder of bronchial asthma, acute bronchitis, chronic bronchitis or emphysema.

Who should use Tulobuterol tapes 2 mg from Japan?

Studies of Japanese scientists showed that Tulobuterol works effectively when used for a long period of time, from 6 months to 1 year (T. Horiguchi, R. Kondo et al. “Clinical Evaluation of a Transdermal Therapeutic System of the ß2-Agonist Tulobuterol in Patients with Mild or Moderate Persistent Bronchial Asthma”. Arzneimittelforschung 2004; 54(5): 280-285). Also, the preparation adsorbing through skin has significantly less adverse effects when compared to oral preparations.